Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Preserving genome integrity: The vital role of SUMO-targeted ubiquitin ligases. | Cell Insight | 2023 | 38047137 | PubTator, text mining | PubMed |
| The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis. | J Transl Med | 2023 | 38041093 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. | JCO Precis Oncol | 2023 | 38039432 | PubTator, text mining | PubMed |
| NTHL1 is a recessive cancer susceptibility gene. | Sci Rep | 2023 | 38036545 | PubTator, text mining | PubMed |
| Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting. | Nat Commun | 2023 | 38030626 | PubTator, text mining | PubMed |
| Multigene testing panels reveal pathogenic variants in sporadic breast cancer patients in northern China. | Front Genet | 2023 | 38028594 | PubTator, text mining | PubMed |
| Network-targeting combination therapy of leptomeningeal glioblastoma using multiple synthetic lethal strategies: a case report. | Front Oncol | 2023 | 38023264 | PubTator, text mining | PubMed |
| Analysis of Turkish Breast Cancer Patients With ATM-Heterozygous Germline Mutation According to Clinicopathological Features. | Cureus | 2023 | 38021491 | PubTator, text mining | PubMed |
| Immune microenvironment heterogeneity reveals distinct subtypes in neuroblastoma: insights into prognosis and therapeutic targets. | Aging (Albany NY) | 2023 | 38019470 | PubTator, text mining | PubMed |
| Frequencies of Diagnostically Significant Polymorphisms of Hereditary Breast Cancer Forms in BRCA1 and BRCA2 Genes in the Kazakh Population. | Asian Pac J Cancer Prev | 2023 | 38019249 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| The effects of ARID1A mutation in gastric cancer and its significance for treatment. | Cancer Cell Int | 2023 | 38008753 | PubTator, text mining | PubMed |
| Comparative Analysis of Alpha and Beta HPV E6 Oncoproteins: Insights into Functional Distinctions and Divergent Mechanisms of Pathogenesis. | Viruses | 2023 | 38005929 | PubTator, text mining | PubMed |
| Exome Sequencing Reveals Novel Germline Variants in Breast Cancer Patients in the Southernmost Region of Thailand. | J Pers Med | 2023 | 38003901 | PubTator, text mining | PubMed |
| Association of Germline Variation in Driver Genes with Breast Cancer Risk in Chilean Population. | Int J Mol Sci | 2023 | 38003265 | PubTator, text mining | PubMed |
| The Pathological Role of miRNAs in Endometriosis. | Biomedicines | 2023 | 38002087 | PubTator, text mining | PubMed |
| A Systematic Review and Critical Assessment of Breast Cancer Risk Prediction Tools Incorporating a Polygenic Risk Score for the General Population. | Cancers (Basel) | 2023 | 38001640 | PubTator, text mining | PubMed |
| Dpep Inhibits Cancer Cell Growth and Survival via Shared and Context-Dependent Transcriptome Perturbations. | Cancers (Basel) | 2023 | 38001578 | PubTator, text mining | PubMed |
| RTEL1 gene polymorphisms and neuroblastoma risk in Chinese children. | BMC Cancer | 2023 | 38001404 | PubTator, text mining | PubMed |
| Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer. | Cancer Invest | 2023 | 37997757 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=17